A detailed history of Black Rock Inc. transactions in Tango Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 3,987,852 shares of TNGX stock, worth $12.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,987,852
Previous 3,861,362 3.28%
Holding current value
$12.1 Million
Previous $30.7 Million 11.6%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$6.66 - $10.15 $842,423 - $1.28 Million
126,490 Added 3.28%
3,987,852 $34.2 Million
Q1 2024

May 10, 2024

SELL
$7.51 - $12.88 $660,234 - $1.13 Million
-87,914 Reduced 2.23%
3,861,362 $30.7 Million
Q4 2023

Feb 13, 2024

BUY
$6.52 - $12.01 $2.55 Million - $4.71 Million
391,757 Added 11.01%
3,949,276 $39.1 Million
Q3 2023

Nov 13, 2023

SELL
$2.93 - $11.26 $190,324 - $731,415
-64,957 Reduced 1.79%
3,557,519 $40.1 Million
Q2 2023

Aug 11, 2023

BUY
$2.67 - $4.7 $223,115 - $392,750
83,564 Added 2.36%
3,622,476 $12 Million
Q1 2023

May 12, 2023

SELL
$3.76 - $8.06 $46,093 - $98,807
-12,259 Reduced 0.35%
3,538,912 $14 Million
Q4 2022

Feb 13, 2023

BUY
$3.41 - $8.29 $2.15 Million - $5.23 Million
630,761 Added 21.6%
3,551,171 $25.7 Million
Q3 2022

Nov 14, 2022

SELL
$3.25 - $5.46 $779,925 - $1.31 Million
-239,977 Reduced 7.59%
2,920,410 $10.6 Million
Q2 2022

Aug 12, 2022

BUY
$3.86 - $8.01 $6.44 Million - $13.4 Million
1,667,201 Added 111.65%
3,160,387 $14.3 Million
Q1 2022

May 12, 2022

BUY
$7.01 - $10.94 $2.39 Million - $3.73 Million
340,746 Added 29.57%
1,493,186 $11.3 Million
Q4 2021

Feb 10, 2022

SELL
$9.55 - $14.29 $2.3 Million - $3.44 Million
-240,728 Reduced 17.28%
1,152,440 $12.6 Million
Q3 2021

Nov 09, 2021

BUY
$9.56 - $17.3 $13.3 Million - $24.1 Million
1,393,168 New
1,393,168 $18 Million

Others Institutions Holding TNGX

About Tango Therapeutics, Inc.


  • Ticker TNGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 88,067,296
  • Market Cap $268M
  • Description
  • Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...
More about TNGX
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.